Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8454802 | Lung Cancer | 2015 | 10 Pages |
Abstract
Malignant pleural mesothelioma (MPM) is a rare malignancy, with extremely poor survival rates. There are limited treatment options, with no second line standard of care for those who fail first line chemotherapy. Recent advances have been made to characterise the underlying molecular mechanisms of mesothelioma, in the hope of providing new targets for therapy. With the discovery that non-coding regions of our DNA are more than mere junk, the field of research into non-coding RNAs (ncRNAs) has exploded in recent years. Non-coding RNAs have diverse and important roles in a variety of cellular processes, but are also implicated in malignancy. In the following review, we discuss two types of non-coding RNAs, long non-coding RNAs and microRNAs, in terms of their role in the pathogenesis of MPM and their potential as both biomarkers and as therapeutic targets in this disease.
Keywords
EGFRhypoxia inducible factor αDNMT3HVAFgrowth arrest-specific 5GAS5DNA methyltransferase 1HULCHIF1αCCND1aCGHDnmt1Cyclin D1EPPFAKCREBFFPEAdenocarcinomaArray comparative genomic hybridizationCompeting endogenous RNAceRNAformalin fixed paraffin embeddedMesothelial hyperplasiacAMP response element binding proteinExtrapleural pneumonectomyfocal adhesion kinaseEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Leah Quinn, Stephen P. Finn, Sinead Cuffe, Steven G. Gray,